Multicenter phase II trial of three-weekly docetaxel and weekly trastuzumab in HER-2-overexpressing metastatic breast cancer patients: Japan East cancer center breast cancer consortium (JECBC 01 trial)

T.Tabei; M.Kimura; M.Sano; T.Asaga; J.Ando; H.Fujii; N.Yamamoto; M.Kurosumi; K.Inoue; N.Sato

首页> 外文期刊>European Journal of Cancer Supplements >Multicenter phase II trial of three-weekly docetaxel and weekly trastuzumab in HER-2-overexpressing metastatic breast cancer patients: Japan East cancer center breast cancer consortium (JECBC 01 trial)

【24h】

Multicenter phase II trial of three-weekly docetaxel and weekly trastuzumab in HER-2-overexpressing metastatic breast cancer patients: Japan East cancer center breast cancer consortium (JECBC 01 trial)

机译：多中心紫杉醇和曲妥珠单抗每周三期，多于HER-2高表达转移性乳腺癌患者的多中心II期试验：日本东癌中心乳腺癌联合会（JECBC 01试验）

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2004年第3期|共1页
作者
T.Tabei; M.Kimura; M.Sano; T.Asaga; J.Ando; H.Fujii; N.Yamamoto; M.Kurosumi; K.Inoue; N.Sato;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Multicenter phase II trial of three-weekly docetaxel and weekly trastuzumab in HER-2-overexpressing metastatic breast cancer patients: Japan East cancer center breast cancer consortium (JECBC 01 trial) [J] . T.Tabei, M.Kimura, M.Sano, European Journal of Cancer Supplements . 2004,第3期

机译：多中心紫杉醇和曲妥珠单抗每周三期，多于HER-2高表达转移性乳腺癌患者的多中心II期试验：日本东癌中心乳腺癌联合会（JECBC 01试验）
2. Multicenter phase II trial of thrice-weekly docetaxel and weekly trastuzumab as preoperative chemotherapy in patients with HER 2-overexpressing breast cancer--Japan East Cancer Center Breast Cancer Consortium (JECBC) 02 Trial [J] . Sano M, Tabei T, Suemasu K, 癌と化学療法 . 2006,第10期

机译：三元期二期试验三十二世多王子和每周曲妥珠单抗作为术前化疗，患者2-过度表达乳腺癌 - 日本东癌中心乳腺癌联盟（JECBC）02试验
3. Multicenter phase II trial of thrice-weekly docetaxel and weekly trastuzumab as preoperative chemotherapy in patients with HER 2-overexpressing breast cancer--Japan East Cancer Center Breast Cancer Consortium (JECBC) 02 Trial [J] . Sano M, Tabei T, Suemasu K, 癌と化学療法 . 2006,第10期

机译：多中心Ⅱ期多西他赛和曲妥珠单抗每周两次作为HER 2过表达乳腺癌患者的术前化学疗法的多中心II期试验-日本东癌中心乳腺癌联合会（JECBC）02试用
4. Effects of laser immunotherapy on late-stage, metastatic breast cancer patients in a Phase Ⅱ clinical trial [C] . Gabriela L. Ferrel, Feifan Zhou, Xiaosong Li, Biophotonics and immune responses IX . 2014

机译：Ⅱ期临床试验中激光免疫疗法对晚期转移性乳腺癌患者的影响
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. Multicenter Phase II Study with Weekly Bendamustine and Paclitaxel as First- or Later-Line Therapy in Patients with Metastatic Breast Cancer: RiTa II Trial [O] . Sibylle Loibl, Gabriele Doering, Lothar Müller, 2011

机译：多中心II期研究每周使用苯达莫司汀和紫杉醇作为转移性乳腺癌患者的一线或后线治疗：RiTa II试验
7. Multicenter Phase II Trial of Weekly Paclitaxel for Advanced or Metastatic Breast Cancer: the Saitama Breast Cancer Clinical Study Group (SBCCSG-01) [O] . K. Sato 2003

机译：每周紫杉醇的多中心期II试验晚期或转移性乳腺癌：埼玉乳腺癌临床研究组（SBCCSG-01）

Multicenter phase II trial of three-weekly docetaxel and weekly trastuzumab in HER-2-overexpressing metastatic breast cancer patients: Japan East cancer center breast cancer consortium (JECBC 01 trial)

著录项

相似文献

相关主题

期刊订阅